WASHINGTON, APRIL 27, 2004 - It's not too late
to fix the Medicare Modernization Act of 2003 so that the program
avoids a deepening fiscal crisis and helps seniors who can't afford
their prescriptions. In three new papers, The Heritage Foundation
maps out how Congress can do just that - by building on some of the
better features in the legislation.
Left unchecked, the costs of the universal prescription-drug
entitlement approved for seniors last year will explode, says
Robert Moffit, director of Heritage's Center for Health Policy
Studies, in the first paper. "The entitlement alone will add $8.1
trillion to Medicare's unfunded liabilities over the next 75 years,
according to the program's trustees," he says. "The added burden on
current and future taxpayers will be enormous, to say the
least."
Fortunately, the universal drug benefit doesn't go into effect
until 2006, so there's still time to remedy the problem, Moffit
says. The solution can be found in one provision that does go into
effect this year: the prescription-drug discount cards.
In addition to authorizing these cards, which are projected to
result in savings of 10 percent to 25 percent on drug costs, the
Medicare Modernization Act offers them free - and with a $600
subsidy for drug purchases - for low-income seniors currently
lacking drug benefits. Moffit says Congress should make this
program permanent, increase the subsidies and abandon the universal
benefit for which everyone from Bill Gates to minimum-wage workers
would be eligible.
"Making the discount card the foundation of a new, targeted and
market-based Medicare drug policy would slow the needless
displacement of existing drug coverage and the otherwise inevitable
imposition of price controls on drugs," he says.
In the second paper, Joseph Antos of the American Enterprise
Institute argues that the Medicare Modernization Act has useful
cost-containment provisions built in - if they're handled properly.
For example, he notes, the law establishes an early-warning system
that reflects the financial activities of all parts of Medicare -
as opposed to, in the past, taking into account only Part A, which
covers hospital costs.
Part A is funded by the Medicare payroll tax, a tax on Social
Security benefits and other sources dedicated specifically to it.
In Part B, premiums paid by beneficiaries cover a quarter of the
cost, with the rest coming from general tax revenues. (The Act did
introduce some means-testing for Part B: Those making more than
$80,000 per year will pay higher premiums after 2007). In the new
Part D for prescription drugs, all costs are to be paid from
general revenues.
General revenue covers about 35 percent of Medicare's costs today.
If the Medicare trustees find that general revenue will cover 45
percent of spending at any time in two straight seven-year periods
- say 2010 to 2017 and 2011 to 2018 - the president must submit
legislation that addresses Medicare financing. But there's no
requirement that the president's legislation be passed and nothing
to stop Congress from calling for even more spending. Antos
recommends that the president's proposal be required to contain a
"preponderance of cost-reducing proposals."
Yet he cautions against automatic spending cuts - i.e., a provision
that would automatically reduce benefits if Medicare spending
reaches the 45 percent threshold. This doesn't bring efficiency and
doesn't force Congress to truly address the problems that led to
the excessive costs, Antos says.
Finally, he suggests that Congress adopt the payment approach used
in the Federal Employees Health Benefits Program, which serves 10
million federal employees, retirees and their families. Instead of
setting the amount it will pay for every single medical service or
good, FEHBP sets the amount it will contribute to employee
premiums. Employees then choose the plan that best meets their
health and budget concerns, which means they can pay more if they
want "Cadillac" coverage.
The third paper, by Antos and Grace-Marie Turner, president of the
Galen Institute, addresses the drug discount cards. Turner and
Antos say critics have raised four concerns about the cards:
- A single card may not cover all the drugs a beneficiary
uses.
- After seniors sign up for a card, its sponsors may then cease
to cover drugs those seniors need.
- Card plans can change drug prices weekly, even though
beneficiaries are locked into their plans for a year.
- Rising drug prices may erode the savings from the card.
First, they point out, this is a discount program, not a drug
benefit. The card can't cover every drug and still provide savings.
Second, drug-card plans are required to cover at least one drug in
all therapeutic categories to ensure seniors can get the drugs they
need. Third, most of the plans that will offer cards also plan to
participate in Medicare Part D in 2006 and beyond. They have
reputations to protect and customers to keep. That means they will
monitor and limit price hikes to ensure they reflect market costs.
Fourth, the early reports are that card sponsors are competing to
negotiate the lowest prices on drugs to attract as many enrollees
as possible.
All three papers are
available online